European Journal of Clinical Pharmacology

, Volume 62, Issue 10, pp 863–870 | Cite as

Prevalence and patterns of antidepressant drug use during pregnancy

  • Tessa Ververs
  • Hans Kaasenbrood
  • Gerard Visser
  • Fred Schobben
  • Lolkje de Jong-van den Berg
  • Toine EgbertsEmail author
Pharmacoepidemiology and Prescription



The aim of this study was to determine the extent and patterns of antidepressant use before, during and after pregnancy in a large population in The Netherlands.


Health care records and prescription data from one of the largest Dutch health insurance companies were analysed. The study cohort consisted of 29,005 women who had live births in the period between January 2000 and July 2003. Antidepressant drug use during a specified period was defined as there being a record of a prescription during that period.


During the first trimester of pregnancy 2% of all pregnant women of the study cohort were found to have taken antidepressants; in the second and third trimesters, this figure had dropped to 1.8% of all pregnancies. Antidepressant use before as well as during pregnancy was almost twofold higher in women over 35 years of age than in those under 35 years. Almost 60% of the women who used antidepressants before pregnancy stopped taking them in the first trimester, and a smaller number stopped thereafter. Of all women using antidepressants during pregnancy, one third started this medication during gestation. In the 3 months following delivery, the prevalence of antidepressant use was the same as before pregnancy (2.9%). There was no shift to benzodiazepines in the group of women who stopped taking antidepressants during pregnancy. Although paroxetine and fluoxetine were the most frequently used antidepressants among the study group, all modern antidepressants were used.


A considerable number of women are being exposed to antidepressants throughout pregnancy up until delivery. One consequence of this is that their newborns need special care and supervision during the first days of life. However, women who stop taking the medication may risk a relapse of their illness, and this may also have a negative effect on the child.


Antidepressants Drug use Pregnancy Pharmacoepidemiology 



We are grateful to the VGZ Health Insurance Company for providing the health care and medication records we used in our study.


  1. 1.
    Hansen DG, Sondergaard J, Vach W, Gram LF, Rosholm JU, Kragst J (2003) Antidepressant drug use in general practice: inter-practice variation and association with practice characteristics. Eur J Clin Pharmacol 59:143–149PubMedGoogle Scholar
  2. 2.
    De las Cuevas C, Sanz E (2004) Do therapeutic indications of antidepressants change from one year to another? Pharmacoepidemiol Dr S 13:309–314CrossRefGoogle Scholar
  3. 3.
    Foundation for Pharmaceutical Statistics, Farmacie in cijfers. [Pharmacy in figures. Drug use of antidepressants is increasing] 2005 Pharmaceutisch Weekblad 140:767 or
  4. 4.
    Kallen B, Otterblad Olausson P (2006) Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol 21:221–222PubMedCrossRefGoogle Scholar
  5. 5.
    Williams M, Wooltorton E (2005) Paroxetine(Paxil) and congenital malformations. Can Med Assoc J 173:1320–1321CrossRefGoogle Scholar
  6. 6.
    Casper RC, Fleisher BE, Lee-Ancajas JC, Gilles A, Gaylor E, DeBattista A, Hoyme HE (2003) Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 142:402–408PubMedCrossRefGoogle Scholar
  7. 7.
    Zeskind PS, Stephens LE (2004) Maternal Selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 113:368–375PubMedCrossRefGoogle Scholar
  8. 8.
    Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA (2006) Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 354:579–587PubMedCrossRefGoogle Scholar
  9. 9.
    Nonacs R, Cohen LS (2003) Assessment and treatment of depression during pregnancy: an update. Psychiatr Clin N Am 26:547–562CrossRefGoogle Scholar
  10. 10.
    Sanz EJ, De-las-Cuevas D, Kiuru A, Bate A, Edwards R (2005) Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 365:482–487PubMedGoogle Scholar
  11. 11.
    Olesen C, Sorensen HT, de Jong-van den Berg L, Olsen J, Steffensen FH (1999) Prescribing during pregnancy and lactation with reference to the Swedish classification system. A population-based study among Danish women. The Euromap Group. Acta Obstet Gynecol Scand 78:686–692PubMedCrossRefGoogle Scholar
  12. 12.
    Beyens MN, Guy C, Ratrema M, Ollagnier M (2003) Prescription of drugs to pregnant women in France: the HIMAGE study. Therapie 58:505–511PubMedCrossRefGoogle Scholar
  13. 13.
    Schirm E, Meijer WM, Tobi H, de Jong-van den Berg LT (2004) Drug use by pregnant women and comparable non-pregnant women in the Netherlands with reference to the Australian classification system. Eur J Obstet Gynecol Reprod Biol 114:182–188PubMedCrossRefGoogle Scholar
  14. 14.
    Headley J, Northstone K, Simmons H, Golding J; ALSPAC Study Team (2004) Medication use during pregnancy: data from the Avon longitudinal study of parents and children. Eur J Clin Pharmacol 60:355–361PubMedCrossRefGoogle Scholar
  15. 15.
    Egen-Lappe V, Hasford J (2004) Drug prescription in pregnancy: analysis of a large statutory sickness fund population. Eur Clin Pharmacol 60:659–666CrossRefGoogle Scholar
  16. 16.
    Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, McPhillips H, Raebel MA, Roblin D, Smith DH, Yood MU, Morse AN, Platt R (2004) Prescription drug use in pregnancy. Am J Obstet Gynecol 191:398–407PubMedCrossRefGoogle Scholar
  17. 17.
    Czeizel AE, Petik D, Vargha P (2003) Validation studies of drug exposures in pregnant women. Pharmacoepidemiol Dr S 12:409–416CrossRefGoogle Scholar
  18. 18.
    Schirm E, Tobi H, de Jong-van den Berg LTW (2004) Identifying parents in pharmacy data: a tool for the continuous monitoring of drug exposure to unborn children. J Clin Epidemiol 57:737–741PubMedCrossRefGoogle Scholar
  19. 19.
    Mittendorf R, Williams MA, Berkey CS, Cotter PF (1990) The length of uncomplicated human gestation. Obstet Gynecol 75:929–932PubMedGoogle Scholar
  20. 20.
    Australian Drug Evaluation Committee. Medicines in Pregnancy Working Party, Prescribing Medicines in Pregnancy. Australian categorisation of drugs, 4th ed. [cited 3 September 2004]. Available from URL:
  21. 21.
    Statistics Netherlands (CBS) Voorburg, the Netherlands. Available from URL:
  22. 22.
    Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-Asciak P, Shuhaiber S, Koren G (2002) Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 159:1889–1895PubMedCrossRefGoogle Scholar
  23. 23.
    Nordeng H, Spigset O (2005) Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy. Drug Safety 28:565–581PubMedCrossRefGoogle Scholar
  24. 24.
    Cohen LS, Altshuler LL, Stowe ZN, Faraone SV (2004) Reintroduction of antidepressant therapy across pregnancy in women who previously discontinued treatment. A preliminary retrospective study. Psychother Psychosom 73:255–258PubMedCrossRefGoogle Scholar
  25. 25.
    Jaiswal S, Coombs RC, Isbister GK (2003) Paroxetine withdrawal in a neonate with historical and aboratory confirmation. Eur J Pediatr 162:723–724PubMedCrossRefGoogle Scholar
  26. 26.
    Gentile S (2005) SSRIs in pregnancy and lactation: emphasis on neurodevelopmental outcome. CNS Drugs 19:623–633PubMedCrossRefGoogle Scholar
  27. 27.
    Hines RN, Adams J, Buck GM, Faber W, Holson JF, Jacobson SW, Keszler M, McMartin K, Segraves RT, Singer LT, Sipes IG, Williams PL (2004) NTP-CERHR Expert Panel Report on the Reproductive and Developmental Toxicity of Fluoxetine. Birth Defects Res Part B71:193–280CrossRefGoogle Scholar
  28. 28.
    Kallen B (2004) Fluoxetine use in early pregnancy. Birth Defects Res Part B 71:395–396CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Tessa Ververs
    • 1
  • Hans Kaasenbrood
    • 2
  • Gerard Visser
    • 3
  • Fred Schobben
    • 1
  • Lolkje de Jong-van den Berg
    • 4
  • Toine Egberts
    • 5
    Email author
  1. 1.Department of Clinical Pharmacy, Clinical Chemistry and Laboratory MedicineUniversity Medical Center (UMC) UtrechtUtrechtThe Netherlands
  2. 2.VGZ Health Insurance CompanyNijmegenThe Netherlands
  3. 3.Department of Perinatology and GynaecologyUniversity Medical Center (UMC) UtrechtUtrechtThe Netherlands
  4. 4.Department of Social Pharmacy, Pharmacotherapy and PharmacoepidemologyGroningen University Institute for Drug Exploration (Guide), University of GroningenGroningenThe Netherlands
  5. 5.Department of Pharmacoepidemology and PharmacotherapyUtretcht Institute for Pharmaceutical Science (UIPS)UtrechtThe Netherlands

Personalised recommendations